|| ISSN(online): 2589-8698 || ISSN(print): 2589-868X ||

Available online on http://www.ijmbs.info

International Journal of Medical and Biomedical Studies; 2024; 8(3); 09-16

Review Article

ENT Manifestations of Sjögren's Syndrome: A Comprehensive Narrative Review

H.I. Farrukh

Director, Consultant Head & Neck Surgeon, Advance ENT Hospital, Champanagar, Bhagalpur, Bihar, India

Received: 05-01-2024 / Revised 30-01-2024 / Accepted 22-02-2024
Corresponding author: H.I. Farrukh
DOI: https://doi.org/10.32553/ijmbs.v8i3.2794
Conflict of interest: Nil

Abstract:

Background: Sjögren's Syndrome (SjS) is a chronic autoimmune disorder predominantly affecting exocrine glands, leading to symptoms such as keratoconjunctivitis sicca and xerostomia. This review focuses on the ear, nose, and throat (ENT) manifestations of SjS, which significantly impact patient quality of life and pose diagnostic challenges.

Aim: The review aims to consolidate current knowledge on the ENT manifestations of SjS, exploring pathophysiological underpinnings, clinical presentations, and treatment strategies, while addressing the diagnostic challenges associated with the disease.

Review Summary: ENT manifestations in SjS include nasal dryness, recurrent sinusitis, otitis, and laryngeal dryness, which may precede other systemic manifestations, aiding in early diagnosis and management. This review highlights the importance of recognizing these symptoms for timely intervention, which can significantly improve disease prognosis.

Future Implications: Understanding ENT manifestations can enhance multidisciplinary management approaches and foster development in diagnostic and therapeutic strategies, potentially improving patient outcomes and quality of life.

Clinical Policy and Development: Enhanced awareness and training on the ENT aspects of SjS are recommended for healthcare professionals. Development of more sensitive diagnostic tools and personalized treatment plans could also address the variability in symptom presentation and response to treatment.

Keywords: Sjögren's Syndrome, ENT Manifestations, Xerostomia, Keratoconjunctivitis Sicca, Multidisciplinary Management

Introduction

Sjögren's Syndrome (SjS) is a systemic autoimmune disorder primarily characterized by the infiltration of lymphocytes into the exocrine glands, leading to significant dryness primarily in the eyes and mouth [1]. This disease typically manifests as keratoconjunctivitis sicca (dry eyes) and xerostomia (dry mouth), but it can affect multiple other organ systems, presenting a variety of symptoms. It is more prevalent in middle-aged women but can occur in any demographic. Diagnosis is often confirmed through various serological tests and biopsy of the salivary gland.

The ENT manifestations of SjS are critical to understand due to their impact on

patients' quality of life and the potential diagnostic challenge they present. Early ENT symptoms often precede other systemic manifestations and can lead to earlier diagnosis and management of the disease. Recognizing these symptoms, which include nasal dryness, recurrent sinusitis, otitis, and laryngeal dryness, is crucial for timely intervention and can significantly affect disease prognosis [2]. Thus, a comprehensive understanding of these manifestations not only aids in the comprehensive care of patients but also enhances the multidisciplinary approach necessary for managing SjS effectively.

Understanding and addressing the ENT manifestations of SjS are therefore essential components of both the diagnostic process and the holistic treatment approach needed for these patients.

The aim of the review was to thoroughly synthesize existing research on the ENT manifestations of Sjögren's Syndrome, examining the pathophysiological underpinnings, clinical presentations, challenges in diagnosis, and current treatment strategies. The review endeavors to answer key questions about the prevalence and impact of ENT symptoms on patient quality of life, the diagnostic hurdles that complicate early detection and accurate diagnosis, and the effectiveness of both established and novel treatments in managing these symptoms. Addressing these questions will not only deepen the understanding of SjS within the medical community but also enhance patient care by highlighting crucial aspects of ENT involvement in this complex autoimmune disorder.

Methodology

The methodology of this narrative review commenced with a systematic search of peer-reviewed literature on the ENT manifestations associated with Sjögren's Syndrome. Key databases such as PubMed, Scopus, Web of Science, and Google Scholar were utilized for the search. Relevant studies were identified using a combination of keywords including "Sjögren's Syndrome", "ENT manifestations", "otolaryngological symptoms", "xerostomia", "dry mouth", "keratoconjunctivitis sicca", "hearing loss", "sinusitis", and "laryngitis". The search focused on literature published from January 2014 to the present to ensure inclusion of the most recent advancements and findings. Only articles published in English were considered.

The selection process involved stringent inclusion and exclusion criteria to refine the pool of articles. Inclusion criteria encompassed all articles that provided data on the prevalence, diagnosis, pathophysiology, or management of ENT manifestations in patients with Sjögren's Syndrome, including studies, review articles, case reports, and clinical guidelines. Exclusion criteria filtered out articles that did not focus on ENT manifestations, as well as editorials, opinion pieces, and non-peer-reviewed documents.

Data extraction was meticulously conducted to gather comprehensive information from each selected article, including author(s), year of publication, study location, study design, participant demographics, diagnostic methods, types of ENT manifestations reported, interventions used, and key findings. The synthesis of extracted data was narrative, aimed at identifying and discussing trends, common findings, and discrepancies within the collected literature. This synthesis addressed the underlying pathophysiological mechanisms of ENT symptoms, the challenges associated with their diagnosis, and the effectiveness of various treatment strategies.

To ensure the integrity and scientific merit of the included studies, a quality assessment was conducted using appropriate evaluation tools. The quality of quantitative studies was assessed using tools such as the Jadad scale for

randomized controlled trials, while qualitative studies were evaluated using CASP (Critical Appraisal Skills Programme) checklists. Additionally, the review included an assessment of potential biases within the studies and the evidence base to ensure the reliability and applicability of the review's conclusions.

Discussion

Epidemiology of ENT Manifestations in Sjögren's Syndrome

Prevalence and Incidence Rates

In India, Sjögren's Syndrome, particularly primary Sjögren's syndrome, has historically been reported less frequently compared to Western countries. However, recent studies have begun to provide more data. It has been observed that even in specialized clinics for rheumatic diseases, the prevalence of SjS among all patients is quite low, approximately 0.5% [3]. This suggests that the disease may be underdiagnosed or possibly underreported, reflecting a significant discrepancy in recognition or diagnostic criteria compared to global data.

Demographic Patterns

The demographic patterns of SjS in India show some unique characteristics. The disease tends to present at an earlier age compared to Western populations, nearly a decade earlier. Common presentations include dry eyes, dry mouth, and systemic features similar to those observed internationally, with delayed complications like renal tubular acidosis sometimes leading to diagnosis. The gender distribution remains consistent with global trends, predominantly affecting women [3].

These findings highlight the importance of developing localized diagnostic criteria and increasing awareness among healthcare professionals to improve the identification and management of SjS in India. Enhanced training and resources could lead to more accurate epidemiological assessments and better patient outcomes.

Pathophysiology of Sjögren's Syndrome

Autoimmune Process in Sjögren's Syndrome

Sjögren's Syndrome is an autoimmune disorder characterized by the immune system's attack on its own exocrine glands, primarily the salivary and lacrimal glands. This autoimmune reaction leads to chronic inflammation and eventual destruction of glandular cells, causing decreased production of saliva and tears. The pathophysiology involves multiple immune pathways, including both the innate and adaptive immune systems. Key features include the activation of T and B lymphocytes, the presence of autoantibodies, and the upregulation of pro-inflammatory cytokines which further drive the inflammatory process in glandular tissues [4].

Specifics of ENT Region Involvement

In Sjögren's Syndrome, the ENT manifestations primarily arise from the dysfunction of the salivary glands (part of the exocrine system), which leads to xerostomia (dry mouth). The dryness can exacerbate dental caries, oral candidiasis, and difficulty in swallowing and speaking. The pathophysiological basis for these symptoms includes both the direct effects of immune-mediated glandular destruction and functional impairment due to cytokine-induced disruptions in salivary secretion.

Exocrine Gland Dysfunction Related to ENT Manifestations

The exocrine gland dysfunction in SjS is predominantly due to lymphocytic infiltrates that disrupt the glandular structure and function, leading to reduced secretion. This process is compounded by the presence of autoantibodies against ribonucleoproteins (anti-Ro/SSA and anti-La/SSB), which are thought to further interfere with glandular cell function. Additionally, there is evidence to suggest that cytokines like IL-4 might play a crucial role in glandular dysfunction, influencing

the severity and progression of symptoms such as dry mouth and contributing to the overall pathogenesis of the syndrome [5].

These insights into the pathophysiology of Sjögren's Syndrome, particularly in the context of India, highlight the complex interplay between immune dysregulation and glandular dysfunction that underpins the various ENT symptoms observed in this condition. Further research focused on local demographic and environmental factors could provide deeper understanding and better management strategies for those suffering from this syndrome.

Clinical Manifestations of Sjögren's Syndrome

Ear Manifestations: Hearing Disturbances and Their Causes

In Sjögren's Syndrome, ear manifestations primarily include sensorineural hearing loss and otalgia. The hearing disturbances are often attributed to inflammatory processes that affect the nerves or can be secondary to the dryness affecting the mucosal linings of the ear canal and middle ear. Sensorineural hearing loss in SjS might be linked to autoimmune inner ear disease, a condition where the body's immune response mistakenly targets the inner ear structures [6].

Nasal and Sinus Manifestations: Dryness, Crusting, and Recurrent Sinus Infections

Patients with SjS frequently experience nasal and sinus symptoms due to the dryness of the nasal mucosa. This dryness can lead to crusting, nasal congestion, and an increased vulnerability to recurrent sinus infections. The lack of adequate mucosal moisture and the consequent thickening of mucus impair the natural sinus drainage and create an environment prone to bacterial growth [7].

Oral and Pharyngeal Manifestations: Xerostomia, Dysphagia, and Salivary Gland Dysfunction

Xerostomia, or dry mouth, is one of the most common and early presenting symptoms of Sjögren's Syndrome. It results from the dysfunction of salivary glands due to lymphocytic infiltration, which significantly reduces saliva production. This reduction in saliva can lead to complications such as difficulty in swallowing (dysphagia), increased dental caries, and oral candidiasis. The decrease in saliva also affects taste and can cause a burning sensation in the mouth [8].

Laryngeal Manifestations: Hoarseness, Dry Cough, and Voice Changes

The laryngeal involvement in SjS includes hoarseness, a persistent dry cough, and changes in the voice. These symptoms are primarily due to the dryness affecting the laryngeal mucosa and vocal cords, making them less flexible and more prone to irritation. In some cases, laryngopharyngeal reflux (LPR) may exacerbate these symptoms by causing further inflammation and irritation in the larynx and pharynx.

These manifestations highlight the diverse and significant impact of SjS on the ENT region, affecting multiple aspects of patients' quality of life and requiring a comprehensive approach to management and treatment.

Diagnostic Challenges in Sjögren's Syndrome

Early Detection and Differential Diagnosis

Early detection and accurate differential diagnosis of SjS present significant challenges due to the often subtle and non-specific nature of its symptoms, which can be easily attributed to other causes such as aging or medication side effects. This can lead to diagnostic delays and mismanagement of the condition. SjS is often identified during differential diagnoses involving multiple exocrine manifestations across various organ systems, making it crucial for a multidisciplinary approach to recognize

and differentiate it from similar disorders [9].

Role of Imaging and Biopsies in Diagnosis

Imaging techniques such as salivary gland ultrasonography (SGUS) and sialography play critical roles in diagnosing SjS by identifying gland abnormalities indicative of the disease. SGUS is particularly valuable due to its non-invasive nature and ability to detect early changes in salivary gland structure. Despite its advantages, the technique requires experienced clinicians for accurate interpretation and may not always be conclusive, necessitating further investigation through minor salivary gland biopsies which remain the gold standard for diagnosis [10].

Diagnostic Criteria Specific to ENT Manifestations

ENT manifestations specific to SS, such as dry mouth and dry eyes, are critical components of the diagnostic criteria, often assessed through tests like Schirmer's test for tear production and unstimulated salivary flow rate measurement. The American-European Consensus Group criteria also integrate these assessments, underscoring their importance in the diagnostic process. However, the variability in clinical presentation and overlap with other conditions can complicate the application of these criteria, requiring a careful and comprehensive evaluation to confirm the diagnosis [9].

These diagnostic challenges highlight the need for heightened awareness among healthcare providers and the adoption of a multidisciplinary approach to accurately identify and manage SjS effectively.

Management and Treatment of Sjögren's Syndrome

Conservative Management Strategies

Conservative management of SjS focuses primarily on alleviating the sicca symptoms, which include dry mouth and dry eyes. Key strategies include meticulous oral hygiene, use of saliva substitutes, and intensive eye care with lubricating eye drops. Environmental modifications such as humidifiers in the home or workplace and avoiding medications that exacerbate dryness are also recommended to improve daily comfort and reduce symptoms.

Pharmacological Treatments

Pharmacological treatments aim to manage both the symptoms and the underlying autoimmune processes. Muscarinic agonists such as pilocarpine and cevimeline are widely used to stimulate saliva and tear production. For systemic symptoms, anti-inflammatory medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, are used. In cases of severe glandular or extraglandular manifestations, immunosuppressants such as hydroxychloroquine, methotrexate, and cyclophosphamide may be employed. Additionally, recent advances have introduced biologics like Rituximab for refractory cases, particularly when there are serious systemic complications [11].

Surgical Interventions

Surgical interventions are relatively limited in the management of SjS but may include procedures such as punctal occlusion to manage severe dry eye. This procedure involves closing the tear ducts to conserve tears and improve eye moisture. In severe cases of dental decay or loss resulting from xerostomia, dental implants or reconstructive surgery may be considered to restore function and appearance [12].

Multidisciplinary Approach to Management

A multidisciplinary approach is critical for effectively managing SjS due to its systemic nature and the variety of organ systems it affects. Collaboration among rheumatologists, dentists, ophthalmologists, and other specialists is essential to address the comprehensive needs of patients. This collaborative approach ensures that all aspects of the

disease, from ocular and oral symptoms to systemic manifestations, are adequately managed and treated [13].

These management strategies collectively aim to reduce symptom burden, manage the underlying autoimmune activity, and improve quality of life for individuals living with Sjögren's Syndrome.

Prognosis of Sjögren's Syndrome: Long-term Outcomes and Quality of Life Considerations

Long-term Outcomes of ENT Manifestations

The long-term outcomes for patients with SjS concerning ENT manifestations generally involve persistent and chronic symptoms such as xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eyes). These conditions are usually progressive with the potential to significantly impair daily functions and increase the risk for secondary complications, including oral and ocular infections. The chronic nature of these symptoms necessitates ongoing management strategies to mitigate their impact. Patients may experience varying degrees of symptom severity over time, influenced by both the progression of the disease and the effectiveness of the treatment regimens employed [14].

Quality of Life Considerations

The quality of life (QoL) for patients with SS, especially those with pronounced ENT manifestations, can be substantially affected. Chronic dryness can lead to difficulties in speaking, eating, and swallowing, which in turn impact social interactions and personal well-being. Moreover, the persistent discomfort and the need for continual management of symptoms (such as using artificial saliva or tear substitutes) can lead to psychological distress. Studies have shown that the health-related quality of life in SjS patients is often lower compared to the general population, with these effects being more pronounced in patients experiencing greater symptom severity or those with additional systemic manifestations of the disease. Managing these symptoms effectively and improving the quality of life for these patients requires a tailored approach, considering both medical treatments and supportive care to address the physical discomfort and psychological impacts of living with SS.

Understanding the long-term outcomes and the quality-of-life impacts is crucial for optimizing the management strategies for Sjögren's Syndrome, aiming not only to treat the physical symptoms but also to support the overall well-being of the patients.

Conclusion

Sjögren's Syndrome presents significant diagnostic and therapeutic challenges due to its complex presentation and impact on various exocrine glands, leading to persistent ENT manifestations such as xerostomia and keratoconjunctivitis sicca. These chronic conditions profoundly affect patients' quality of life, necessitating comprehensive management strategies that address both the physical symptoms and the broader psychosocial impacts. Effective management requires a multidisciplinary approach to ensure that both the symptomatic relief and the emotional and social well-being of the patients are adequately supported. Long-term outcomes vary, largely dependent on the severity of symptoms and the effectiveness of ongoing therapeutic interventions. Thus, understanding and addressing the multifaceted nature of SjS is essential for improving overall patient outcomes and enhancing quality of life.

Limitations: The management of SjS faces limitations due to the variability in disease presentation and the lack of universally effective treatments that target the underlying autoimmune processes. Diagnostic challenges persist with the need for more sensitive tools to detect early glandular involvement. Additionally, the

heterogeneity of patient populations in research studies and the need for more longitudinal data further complicate understanding and treating this complex disease effectively.

Acknowledgment

The authors extend their gratitude to fellow researchers, healthcare professionals, study participants, mentors, and their support networks for their invaluable contributions and unwavering support in advancing our understanding. The collaborative efforts of the scientific community, funding agencies, and regulatory authorities are essential in enhancing knowledge worldwide through research in this field.

List of abbreviation:

SjS: Sjögren's Syndrome
ENT: Ear, Nose, and Throat
QoL: Quality of Life
NSAIDs: Nonsteroidal Anti-Inflammatory Drugs
IL-4: Interleukin-4
LPR: Laryngopharyngeal Reflux
SGUS: Salivary Gland Ultrasonography
SSA: Sjögren's Syndrome A
SSB: Sjögren's Syndrome B
CASP: Critical Appraisal Skills Programme

References

1. Brito-Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, Sivils K, Theander E, Tzioufas A, Ramos-Casals M. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047. Available from: https://doi.org/10.1038/nrdp.2016.47
2. Cornec D, Devauchelle-Pensec V, Mariette X, Jousse-Joulin S, Berthelot JM, Perdriger A, Puéchal X, Le Guern V, Sibilia J, Gottenberg JE, Chiche L. THU0322 Altered Quality of Life Is Mainly Associated with Patient Reported Outcomes in Primary Sjögren's Syndrome Patients: Data from A Large Therapeutic Trial.
3. Mehra S, Hariharan N, Deka S. AB0318 Prevalence of secondary Sjögren's Syndrome in patients with rheumatoid arthritis- A single center study from Northern India. Ann Rheum Dis. 2022. Available from: https://doi.org/10.1136/annrheumdis-2022-eular.4622
4. Kakade G, Joshi P, Balakrishnan C, Khune A. AB0526 Primary Sjögren's Syndrome and organ system involvement: A retrospective study of 153 patients from Western India. Ann Rheum Dis. 2019;78:1725-25. Available from: https://doi.org/10.1136/ANNRHEUM-DIS-2019-EULAR.6399
5. Zhou J, Yu Q. Anti-IL-7 receptor-α treatment ameliorates newly established sjögren's-like exocrinopathy in non-obese diabetic mice. Biochim Biophys Acta Mol Basis Dis. 2018 Jul 1;1864(7):2438-47.
6. Mahmoud T, Wang J, Karnell JL, Wang Q, Wang S, Naiman B, GroSjSP, Brohawn P, Morehouse C, Aoyama J, Wasserfall C, Carter L, Atkinson M, Serreze D, Braley-Mullen H, Mustelin T, Kolbeck R, Herbst R, Ettinger R. Autoimmune manifestations in aged mice arise from early-life immune dysregulation. Sci Transl Med. 2016;8:361ra137-361ra137. Available from: https://doi.org/10.1126/scitranslmed.aag0367
7. Hofauer B, Chaker A, Thürmel K, Knopf A. Manifestations of autoimmune disorders in otorhinolaryngology: Classical symptoms and diagnostic approach. HNO. 2017;65(8):695-708. Available from: https://doi.org/10.1007/s00106-017-0380-6
8. Kamiński B. Laryngological manifestations of Sjögren's syndrome. Reumatologia. 2019;57(1):37–44. Available from: https://doi.org/10.5114/reum.2019.83237
9. Jousse-Joulin S. SP0050 Opportunities and challenges of imaging in primary Sjögren's.

10. Victor D. Sjogren's Syndrome: Multidisciplinary Approach to Diagnosis and Management. Glob J Health Sci. 2023;8(1):50–71. Available from: https://doi.org/10.47604/gjhs.1766
11. Ha YJ, Lee YJ. Pharmacological Management of Sjögren's Syndrome. In: Cha S, editor. Sjögren's Syndrome and Oral Health. Cham: Springer; 2021. Available from: https://doi.org/10.1007/978-3-030-72029-2_11
12. de Mendonça Invernici M, Finger Stadler A, Vale Nicolau G, Naval Machado MÂ, Soares de Lima AA, Compagnoni Martins M. Management of Sjogren's Syndrome Patient: A Case Report of Prosthetic Rehabilitation with 6-Year Follow-Up. Case Rep Dent. 2014;2014:761251. Available from: https://doi.org/10.1155/2014/761251
13. Ramos-Casals M, Brito-Zerón P, Bombardieri S, Bootsma H, De Vita S, Dörner T, Fisher BA, Gottenberg JE, Hernandez-Molina G, Kocher A, Kostov B, Kruize AA, Mandl T, Ng WF, Retamozo S, Seror R, Shoenfeld Y, Sisó-Almirall A, Tzioufas AG, Vitali C, et al. EULAR recommendations for the management of Sjögren's Syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79(1):3–18. Available from: https://doi.org/10.1136/annrheumdis-2019-216114
14. Kim YJ, Choe J, Kim HJ, Song JW. Long-term clinical course and outcome in patients with primary Sjögren syndrome-associated interstitial lung disease. Sci Rep. 2021;11(1):12827. Available from: https://doi.org/10.1038/s41598-021-92024-2.